Tags

Type your tag names separated by a space and hit enter

Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease.
J Alzheimers Dis. 2009; 17(2):423-40.JA

Abstract

Clioquinol (CQ) is a "metal protein attenuating compound" that crosses the blood-brain barrier and binds, with high affinity, copper(II) and zinc(II), two metal ions critically involved in amyloid-beta aggregation and toxicity. CQ was recently proposed for the treatment of Alzheimer's disease, but controversial data have been reported so far concerning its real therapeutic advantages. We describe here results of chronic CQ treatment in the TgCRND8 mouse model of Alzheimer's disease. Remarkably, based on classical behavioral tests, CQ treatment was found to reverse, to a large extent, the working memory impairments that are characteristic of this mouse model. Pairwise, a significant reduction of amyloid-beta plaque burden, both in the cortex and in the hippocampus, was detected as well as an attenuation of astrogliosis. MALDI Mass Spectrometry Imaging technique revealed a specific localization of CQ in the above mentioned brain areas. Modest but significant effects on the absolute and relative brain concentrations of the three most important biometals (i.e., copper, zinc, and iron) were highlighted following CQ treatment. The pharmacological and mechanistic implications of the above findings are thoroughly discussed.

Links

Publisher Full Text

Authors+Show Affiliations

Grossi C
Department of Pharmacology, University of Florence, Florence, Italy.
Francese S
No affiliation info available
Casini A
No affiliation info available
Rosi MC
No affiliation info available
Luccarini I
No affiliation info available
Fiorentini A
No affiliation info available
Gabbiani C
No affiliation info available
Messori L
No affiliation info available
Moneti G
No affiliation info available
Casamenti F
No affiliation info available

MeSH

Alzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnalysis of VarianceAnimalsBody WeightCerebral CortexClioquinolDisease Models, AnimalGlial Fibrillary Acidic ProteinHippocampusHumansMaze LearningMemory DisordersMemory, Short-TermMetalsMiceMice, Inbred C57BLMice, TransgenicReaction TimeSpectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19363260

Citation

Grossi, Cristina, et al. "Clioquinol Decreases Amyloid-beta Burden and Reduces Working Memory Impairment in a Transgenic Mouse Model of Alzheimer's Disease." Journal of Alzheimer's Disease : JAD, vol. 17, no. 2, 2009, pp. 423-40.
Grossi C, Francese S, Casini A, et al. Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis. 2009;17(2):423-40.
Grossi, C., Francese, S., Casini, A., Rosi, M. C., Luccarini, I., Fiorentini, A., Gabbiani, C., Messori, L., Moneti, G., & Casamenti, F. (2009). Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. Journal of Alzheimer's Disease : JAD, 17(2), 423-40. https://doi.org/10.3233/JAD-2009-1063
Grossi C, et al. Clioquinol Decreases Amyloid-beta Burden and Reduces Working Memory Impairment in a Transgenic Mouse Model of Alzheimer's Disease. J Alzheimers Dis. 2009;17(2):423-40. PubMed PMID: 19363260.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. AU - Grossi,Cristina, AU - Francese,Simona, AU - Casini,Angela, AU - Rosi,Maria Cristina, AU - Luccarini,Ilaria, AU - Fiorentini,Anna, AU - Gabbiani,Chiara, AU - Messori,Luigi, AU - Moneti,Gloriano, AU - Casamenti,Fiorella, PY - 2009/4/14/entrez PY - 2009/4/14/pubmed PY - 2009/12/17/medline SP - 423 EP - 40 JF - Journal of Alzheimer's disease : JAD JO - J Alzheimers Dis VL - 17 IS - 2 N2 - Clioquinol (CQ) is a "metal protein attenuating compound" that crosses the blood-brain barrier and binds, with high affinity, copper(II) and zinc(II), two metal ions critically involved in amyloid-beta aggregation and toxicity. CQ was recently proposed for the treatment of Alzheimer's disease, but controversial data have been reported so far concerning its real therapeutic advantages. We describe here results of chronic CQ treatment in the TgCRND8 mouse model of Alzheimer's disease. Remarkably, based on classical behavioral tests, CQ treatment was found to reverse, to a large extent, the working memory impairments that are characteristic of this mouse model. Pairwise, a significant reduction of amyloid-beta plaque burden, both in the cortex and in the hippocampus, was detected as well as an attenuation of astrogliosis. MALDI Mass Spectrometry Imaging technique revealed a specific localization of CQ in the above mentioned brain areas. Modest but significant effects on the absolute and relative brain concentrations of the three most important biometals (i.e., copper, zinc, and iron) were highlighted following CQ treatment. The pharmacological and mechanistic implications of the above findings are thoroughly discussed. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/19363260/Clioquinol_decreases_amyloid_beta_burden_and_reduces_working_memory_impairment_in_a_transgenic_mouse_model_of_Alzheimer's_disease_ L2 - https://content.iospress.com/openurl?genre=article&issn=1387-2877&volume=17&issue=2&spage=423 DB - PRIME DP - Unbound Medicine ER -